NR1H4 and metabolic dysfunction-associated steatotic liver disease: Consequently, both metabolic targets, such as peroxisome proliferator-activated receptors (PPARs) and the farnesoid X receptor, and immune targets, such as chemokines and their receptors, have been explored as therapeutic avenues for MASLD [34,35,36,37].